Bebig
Moscow
About Bebig
Bebig is a preparation and packaging of microsources for brachytherapy using isotope. Brachytherapy is a form of radiotherapy for malignant tumors in which the radiation source is placed within the affected organ. The optimal dose of radiation is delivered directly to the tumor without exposing adjacent tissues and organs. Brachytherapy is used extensively worldwide; it has been used in 800 medical centers in the United States and Western Europe for over 14 years. This project will establish domestic production of microsources, titanium capsules containing a gold wire (x-ray marker) and radionuclide 125I (iodine-125) in the form of silver iodide whose surface has been modified for better ultrasound visualization. Portfolio company will also produce nanostructured microspheres of polymer, glass, or silicon particles that incorporate atoms of radioactive isotopes. Their diameters are about 30 microns. Microsources produced by the project will be used to treat prostate, liver, and pancreatic cancers. Prostate cancer is one of the most common diseases in the country. There are more than 2.5 million cancer patients in Russia for whom effective treatment is essential. The project has high social significance.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Last round: Series Unknown (Jan 2009)
- Website: bebig.ru
- Phone: +7 (495) 780-92-68
Industries & Categories
Biotechnology, Chemical, Chemical Engineering, Health Care, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/bebig-2917525 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.